NVG-2089
Asset
- Stage
- Phase 2
- Modality
- Protein or enzyme
- Target
- Not known
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Chronic inflammatory demyelinating polyneuropathy
Phase 2, Terminated, NCT07027111, clinicaltrials.gov, Oct 17, 2026
In the full profile
- Owner and partners1
- Trials1
Every asset’s record: target, stage, trials and the evidence behind it.